GLP-1 Savings Cards and Copay Cards: How to Actually Pay Less

At list price, a month of a brand-name GLP-1 costs more than many car payments. Almost nobody is supposed to pay that number — but the discounts don’t apply themselves. Here’s how the manufacturer savings programs actually work, who they’re for, and the fine print that catches people.

What a savings card is (and isn’t)

A savings card — also called a copay card or copay coupon — is a discount program run by the drug’s manufacturer. Novo Nordisk runs them for Wegovy and Ozempic; Eli Lilly runs them for Zepbound and Mounjaro. The manufacturer pays part of your out-of-pocket cost as a marketing expense, because a patient who can afford to stay on the drug is worth more to them than the discount costs.

It is not insurance, not a government benefit, and not the same as a pharmacy discount card (GoodRx-style cards rarely move the needle much on GLP-1s). It stacks on top of commercial insurance — which is also its biggest limitation.

Who qualifies

The pattern is consistent across manufacturers:

• Commercial insurance that covers the drug → the best case. The card can drop your copay to a low fixed amount per month, subject to monthly and annual caps.
• Commercial insurance that doesn’t cover the drug → some programs still offer a reduced price, but the discount is smaller than the covered path.
• Medicare, Medicaid, TRICARE, or any government plan → not eligible, full stop. Federal anti-kickback rules prohibit manufacturer copay cards on government insurance. This is the single most common disappointment, and no workaround offered by a third-party site is legitimate.
• No insurance / self-pay → savings cards don’t apply, but the direct cash-pay programs below do.

How to enroll (two minutes, genuinely)

Go to the manufacturer’s official site — wegovy.com, ozempic.com, zepbound.lilly.com, or mounjaro.com — find the savings/coverage section, answer the eligibility questions, and download the card. Give it to your pharmacist with your prescription; it applies at the register. That’s the whole process. Anything that asks you to pay for a “discount code,” phone in your card number to a non-manufacturer site, or “unlock” a coupon is at best a lead-generation funnel and at worst a scam.

The fine print that trips people up

• Caps. The discount has per-fill and annual maximums. If your plan’s copay is high, the card may cover only part of it.
• Programs change constantly. Amounts, eligibility, and even whether a program exists are revised often — verify at each refill cycle rather than trusting a months-old screenshot.
• Copay accumulators and maximizers. The sneakiest one: some insurance plans accept the manufacturer’s money but don’t count it toward your deductible or out-of-pocket maximum. You pay little at the pharmacy for months, then discover your deductible is still nearly untouched. Ask your plan directly: “Do manufacturer copay card payments count toward my deductible?” If the answer is no, budget accordingly — the card still helps, but it isn’t building toward anything.
• Cards can end mid-treatment. A savings program is a marketing decision, not a contract. Build your plan around the possibility of the discount shrinking.

If you don’t qualify: the cash-pay routes

The market shifted meaningfully here: both manufacturers now sell directly to self-pay patients through their own channels (Novo Nordisk via NovoCare’s pharmacy option, Lilly via LillyDirect — including lower-priced vial options for some doses). As of mid-2026 these run to roughly a third to half of list price — still real money, but a different category than list. Check the manufacturer’s own site for current pricing, since it has been moving.

Before going further down-market, read up on compounded semaglutide — cheaper, but not FDA-approved, and the legal ground has been shifting since the shortages ended.

And if the underlying problem is that your insurance should cover it but doesn’t, that’s a different playbook entirely: the insurance coverage guide covers prior authorization, documentation, and appeals — a covered drug plus a savings card beats every cash-pay price.

Keep the receipts (literally)

Cost interruptions are treatment interruptions: a lapsed card or a surprise deductible month is how multi-week gaps happen, and gaps mean rough restarts. Two boring habits protect you: re-verify your card’s terms at each refill, and log your doses so any cost-driven gap is visible in your record — “three weeks off in April when the card capped out” is context your prescriber needs at the next titration decision.

Sources: manufacturer savings and coverage pages (Novo Nordisk / NovoCare, Eli Lilly / LillyDirect); KFF analyses of GLP-1 costs and coverage. Program terms change frequently — always verify current terms on the manufacturer’s official site.